Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus

Mediators of Inflammation

Volumn 12, Issue 5, 2003, Pages 293-298

  Robak, Ewa ^a   Sysa Jȩdrzejewska, Anna ^a   Robak, Tadeusz ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Angiogenesis; Disease activity; FLK 1; fms like tyrosine kinase 1; Soluble VEGF receptors; Systemic lupus erythematosus; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; CYTOTOXIC AGENT; ENDOSTATIN; PROTEIN TYROSINE KINASE; STEROID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; DISEASE ACTIVITY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; HUMAN; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0242441067     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629350310001619726     Document Type: Article

References (35)

1. Plate KH, Warnke PC. Vascular endothelial growth factor. J Neurooncol 1997; 35: 365-372.
2. Jośko J, Gwóźdź B, Jȩdrzejewska- Szypulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6: 1047-1052.
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
4. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-1814.
5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
6. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. Nucleotide sequence and expression of a novel human receptor type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
7. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitorv D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-1586.
8. deVries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
9. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J Biol Chem 1996; 271: 17629-17634.
10. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organziation of the flt-I gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and 5-Ig tyrosine kinase receptors. Gene 1997; 208: 297-305.
11. Hornig C, Behn T, Bartsch W, Yayon A, Weich HA. Detection and quantification of complex and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by elisa. J Immunol Methods 1999; 226: 169-177.
12. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap aVEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398.
13. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1 and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328.
14. Yamaguchi S, Iwata K, Shibuya M. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 2002; 291: 554-559.
15. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443-454.
16. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 1998; 241: 161-170.
17. Hornig C, Weight HA. Soluble VEGF receptors. Angiogenesis 1999; 3: 33-38.
18. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001; 1: 703-718.
19. Kadono T, Kikuchi K, Kubo M, Fuijmoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996; 35: 392-397.
20. Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377.
21. Robak E, Woźniacka A, Sysa-Jȩdrzejewska A, Stȩpien H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Network 2001; 12: 445-452.
22. Robak E, Woźniacka A, Sysa-Jȩdrzejewska A, Stȩpien H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348-355.
23. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Artchritis Rheum 1982; 25: 1271-1277.
24. Liang MH, Socher SA, Larson MG, Schur FH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
25. Robak T, Wierzbowska A, Błasińska-Morawiec, Korycka A, Błoński JZ. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Mediat Inflamm 1999; 8: 277-286.
26. Belgore FM, Lip GY, Bareford D, Wadley M, Stonelake P, Blann AD. Plasma levels of vascular endothelial growth factor (VEGF) and Its receptor Flt-1, in hematological cancers: a comparison with breast cancer. Am J Hematol 2001; 66: 59-61.
27. Wierzbowska A, Robak T, Wrzesień-Kuś A, Krawczyńśka A, Lech-Marańda E, Urbańska-Ryś H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Network 2003; 14: 149-153.
28. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie 2 and Flt-1 extra cellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992-1997.
29. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marme D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 2001; 4: 143-154.
30. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/ soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-18.
31. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D. Vascular endothelial growth factor up regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997; 57: 5421-5425.
32. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001; 33: 409-420.
33. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG. Inhibition of tumour growth by targeting tumor endothelium using a soluble endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49-58.
34. Meeson AP, Argilla M, Ko K, Witte L, Lang RA, VEGF-deprivation-induced apoptosis is a component of programmed capillary regression. Development 1999; 126: 1407-1415.
35. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.